https://www.selleckchem.com/products/azd9291.html
Eribulin was third-line therapy for 78.0% of patients, and fourth-line or later for the remainder. ORR was 54.4%, median PFS was 6.1months (95% CI 5.8, 6.6), and median OS was 10.6months (95% CI 9.9, 11.7) in all patients. Among the 49.9% of patients with TNBC, ORR was 55.1%, median PFS was 5.8months (95% CI 5.1, 6.4), and median OS was 9.8months (95% CI 8.6, 11.. The current retrospective chart review study reinforces the clinical effectiveness of eribulin in patients with MBC, including those with TNBC, when used according to the ap
Me gusta
Comentario
Compartir
